Owners, management and financials
CVR: 39492059
Secondary names: Oresund Pharma ApS, Oresund ApS
Previous names: Øresund Pharma IVS
DKK 39,702,011
Gross profit
Net result: DKK 6,466,876
Machpali ApS (90-99,99%), ESH Holding 2019 ApS (10-14,99%)
CVR · view owners
Patrick Halborg Cohn, Svend Aage Johansen
CVR · view management
Active
Founded 17 April 2018
CVR · view overview
21 employees
CVR · 2026
Director registered: Svend Aage Johansen
CVR · 01/04/2024
View the full event history
Øresund Pharma ApS is a Danish company of the type Anpartsselskab based in Nordhavn, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Øresund Pharma IVS. The management consists of Patrick Halborg Cohn and Svend Aage Johansen. The company is owned by Machpali ApS and ESH Holding 2019 ApS. The company has 21 employees (2026). In 2025, the company reported a gross profit of DKK 39,702,011 and a net result of DKK 6,466,876 compared with DKK 13,707,320 the year before. Equity in the 2025 report amounted to DKK 44,617,595.
Source: annual report 2025, Danish Business Authority
Øresund Pharma ApS demonstrates a strong upward trajectory in profitability and gross profit over the past few years, with gross profit increasing from 7.3 million DKK in 2021 to nearly 39.7 million DKK in 2025. Profitability has also improved significantly, reaching 16.8 million DKK in 2023 before slightly declining to 6.5 million DKK in 2025. The company's equity has shown robust growth, rising from 3.4 million DKK in 2021 to 44.6 million DKK in 2025, indicating a solid financial foundation. However, the absence of disclosed revenue figures raises concerns about transparency and market position within the pharmaceutical distribution industry. Overall, Øresund Pharma appears well-positioned for continued growth, supported by strong margins and a healthy equity base.
AI-generated summary · Generated 16/08/2026
Selskabets formål er at udvikle og kommercialisere farmaceutiske lægemidler og dermed forbunden virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 39.7 mio. | 6.5 mio. | 127.6 mio. | 44.6 mio. | 16 | |
| 202401/01/2024 – 31/12/2024 | 39.6 mio. | 13.7 mio. | 81.1 mio. | 38.2 mio. | 11 | |
| 202301/01/2023 – 31/12/2023 | 38.3 mio. | 16.8 mio. | 42.5 mio. | 24.4 mio. | 9 | |
| 202201/01/2022 – 31/12/2022 | 17.2 mio. | 4.3 mio. | 31 mio. | 7.7 mio. | 6 | |
| 202101/01/2021 – 31/12/2021 | 7.3 mio. | 281 t. | 23.9 mio. | 3.4 mio. | 5 | |
| 202001/01/2020 – 31/12/2020 | 2.8 mio. | -86 t. | 23 mio. | 3.1 mio. | 4 | |
| 201901/01/2019 – 31/12/2019 | 4.9 mio. | 2.6 mio. | 14.4 mio. | 2.7 mio. | 3 |
Compared to 404 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
21 public tenders won
Showing 10 of 21 contracts
See all won contracts on UdbudsScannerSources: TED (the EU tender database) and udbud.dk
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of Øresund Pharma ApS is 39492059.
Øresund Pharma ApS is owned by Machpali ApS and ESH Holding 2019 ApS.
The management of Øresund Pharma ApS consists of Patrick Halborg Cohn and Svend Aage Johansen.
In 2025, Øresund Pharma ApS reported a gross profit of DKK 39,702,011.
Øresund Pharma ApS had 21 employees in 2026 according to the Danish CVR register.
Øresund Pharma ApS was founded on 17 April 2018.
Claim this page to add your logo and social links. Free to get started.
Øresund Pharma ApS has won the tender "Amgros 2027 1.1202.a" issued by Amgros I/S worth 381,745,570 DKK.
Øresund Pharma ApS has won the tender "Amgros 2027 2.1200.a" issued by Amgros I/S worth 73,487,895 DKK.
Øresund Pharma ApS has won the tender "Amgros 2027 1.1203.a" issued by Amgros I/S worth 148,085,649 DKK.
Øresund Pharma ApS has won the tender "Amgros 2027 1.700.a" issued by Amgros I/S worth 419,427,587 DKK.
Øresund Pharma ApS has won the tender "Rammeaftale vedrørende levering af fentanyl placebo" issued by Danish Ministry of Defence Acquisition and Logistics Organisation worth 6,500,000 DKK.
Øresund Pharma ApS has published its annual report for 2025. Gross profit came to DKK 39,702,011, and the net result was DKK 6,466,876.
Contact info changed: new email: [email protected], new website: www.oresundpharma.com (January 14, 2026).
Øresund Pharma ApS has won the tender "Amgros 2026 1.1212.a" issued by Amgros I/S worth 44,707,811 DKK.
Øresund Pharma ApS has won the tender "Amgros 2026 1.470.a" issued by Amgros I/S worth 20,500,000 DKK.
Øresund Pharma ApS has won the tender "Amgros 2026 1.1201.a" issued by Amgros I/S worth 358,514,920 DKK.
Øresund Pharma ApS has won the tender "Amgros 2026 1.1203.a" issued by Amgros I/S worth 368,505,024 DKK.
Øresund Pharma ApS has won the tender "Amgros 2026 1.1210.a" issued by Amgros I/S worth 104,066,115 DKK.
Øresund Pharma ApS has won the tender "Amgros 2026 2.790.b" issued by Amgros I/S worth 66,631,361 DKK.
Øresund Pharma ApS has won the tender "Amgros 2026 1.704.b" issued by Amgros I/S worth 32,900,000 DKK.
As of August 19, 2025, BDO Statsautoriseret Revisionspartnerselskab has been appointed auditor of Øresund Pharma ApS.
As of August 19, 2025, A/S PSE 17 NR. 1056 has stepped down as auditor of Øresund Pharma ApS.
Øresund Pharma ApS has published its annual report for 2024. Gross profit came to DKK 39,622,065, and the net result was DKK 13,707,320.
Øresund Pharma ApS has won the tender "Amgros 2025 1.1215.b" issued by Amgros I/S worth 49,600,000 DKK.
Øresund Pharma ApS has won the tender "Amgros 2025 1.400.a" issued by Amgros I/S worth 1,010,000 DKK.
Øresund Pharma ApS has won the tender "Amgros 2025 1.1302.a" issued by Amgros I/S worth 17,702,414 DKK.
Øresund Pharma ApS has won the tender "Amgros 2025 1.700.a" issued by Amgros I/S worth 313,301,544 DKK.
Øresund Pharma ApS has won the tender "Amgros 2025 1.1200.a" issued by Amgros I/S worth 101,036,383 DKK.
Øresund Pharma ApS has won the tender "Amgros 2025 1.1202.a" issued by Amgros I/S worth 90,124,932 DKK.
Øresund Pharma ApS has won the tender "Amgros 2025 2.3.b" issued by Amgros I/S worth 359,770,187 DKK.
Øresund Pharma ApS has won the tender "Amgros 2025 1.703.b" issued by Amgros I/S worth 12,600,000 DKK.
Øresund Pharma ApS has won the tender "Amgros 2025 1.1142.b" issued by Amgros I/S worth 153,000,000 DKK.
As of April 1, 2024, Svend Aage Johansen is registered as director of Øresund Pharma ApS.
Øresund Pharma ApS has published its annual report for 2023. Gross profit came to DKK 38,259,550, and the net result was DKK 16,750,969.
Øresund Pharma ApS has published its annual report for 2022. Gross profit came to DKK 17,238,144, and the net result was DKK 4,302,384.
Øresund Pharma ApS has published its annual report for 2021. Gross profit came to DKK 7,275,387, and the net result was DKK 281,255.
As of December 9, 2021, A/S PSE 17 NR. 1056 has been appointed auditor of Øresund Pharma ApS.
As of December 9, 2021, CHRISTENSEN KJÆRULFF STATSAUTORISERET REVISIONSAKTIESELSKAB has stepped down as auditor of Øresund Pharma ApS.
Øresund Pharma ApS has published its annual report for 2020. Gross profit came to DKK 2,754,994, and the net result was DKK -86,083.
As of December 18, 2020, Machpali ApS is registered as an owner of Øresund Pharma ApS with an ownership share of 90%.
As of December 18, 2020, ESH Holding 2019 ApS is registered as an owner of Øresund Pharma ApS with an ownership share of 10%.
Øresund Pharma ApS has published its annual report for 2019. Gross profit came to DKK 4,932,387, and the net result was DKK 2,568,553.
Øresund Pharma ApS has published its interim report for the period April 17, 2018 to December 31, 2018.
As of June 19, 2018, CHRISTENSEN KJÆRULFF STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of Øresund Pharma ApS.
On June 19, 2018, the company changed its name from Øresund Pharma IVS to Øresund Pharma ApS.
As of April 17, 2018, Patrick Halborg Cohn is registered as adm. dir. of Øresund Pharma ApS.
Øresund Pharma ApS was founded on April 17, 2018.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Companies in the same industry and area
CVR 45929698
CVR 46098765
CVR 46788176
CVR 44420449
CVR 19064301
